Worldwide Biotech/Biopharma Alliance (Feb. 4, 2013～Jan. 29. 2013)
On Feb. 4, 2013, Karolinska Development AB (publ) entered into an agreement with Mayo Clinic with the aim of identifying commercialization opportunities in Mayo’s life science innovations that will improve patient care. Through this agreement, Karolinska Development will evaluate innovations from Mayo Clinic. The collaboration will increase the possibilities for life science investments in differentiated world-class scientific innovations.
On Feb 1st, 2013 – RaQualia Pharma Inc. (RaQualia) and Interprotein Corporation (Interprotein) announced that the both companies entered into a collaborative research agreement. The partnership will focus on drug discovery research for a specific protein-protein interaction (PPI)* inhibitor in the disease domain of pain.
On Jan. 31, 2013, Antitope Ltd., UK ("Antitope") announced the completion of a research collaboration with Rottapharma Biotech Srl, the Antibody Research Unit of the Italian healthcare company Rottapharm|Madaus, whereby Antitope applied is proprietary EpiScreenTM and in silico iTopeTM/TCEDTM technologies to profile the immunogenicity of therapeutic antibodies as a part of Rotapharm Biotech Srl research and development program in the field of musculoskeletal disorders.
On Jan. 31, 2013, CEL-SCI Corporation announced that its longstanding collaboration with Northeast Ohio Medical University has produced a new investigational breast cancer vaccine which prevents and treats a HER-2/neu expressing breast cancer tumor in a mouse model of the disease. In animal tests this vaccine has shown 1) reduction of number of tumors, 2) reduction of tumor mass, 3) absence of tumor in lymph nodes or peritoneal membranes and 4) changes in angiogenesis.
On Jan. 30, 2013, Merck Serono and the Feinstein Institute for Medical Research have formed a partnership to develop antibodies to treat systemic lupus erythematosus (SLE), an unpredictable disease that has no cure.
On Jan. 29, 2013, GlaxoSmithKline (GSK) announced an agreement to team up with an Indian venture to produce a 6-in-1 vaccine to protect against polio and 5 other diseases. GSK will form a 50-50 venture with India's Biological E to create a shot that combines GSK's polio vaccine with a Biological E vaccine that protects against diphtheria, tetanus, whooping cough, hepatitis B and Haemophilus influenzae type b. The move comes after Indian billionaire Cyrus Poonawalla, founder of the Serum Institute of India, vowed to slash the price of polio immunization to a third or quarter of its price. Poonawalla wants to introduce a polio shot that costs as little as €0.7 (93 cents) in multidose vials, a significant price drop from a €2.5 ($3.36) jab now on the market.